Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private PlacementDecember 05, 2025 5:02 PM EST | Source: Predictmedix AI Inc.Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, is pleased to announce that it has successfully closed the final tranche of its non-brokered private placement (the "Offering").In this f ...

Core Viewpoint - Predictmedix AI Inc. successfully closed the first tranche of its non-brokered private placement, raising gross proceeds of $460,150 by issuing 9,203,000 units at a price of $0.05 per unit, indicating strong internal confidence in the company's future growth and innovation [1][2]. Financing Details - The private placement consisted of 9,203,000 units, each comprising one common share and one half of a common share purchase warrant, raising a total of $460,150 [2]. - Insiders subscribed $60,000 of the tranche, with Sheldon Kales and Dr. Rahul Kushwah each investing $30,000, reflecting confidence in the company's prospects [1][3]. - Each warrant allows the holder to purchase one half of a common share at a price of C$0.15 for 36 months, with potential acceleration of expiry if the share price meets certain conditions [2]. Regulatory Context - The insider participation in the private placement is classified as a "related party transaction" under Multilateral Instrument 61-101, with the company relying on exemptions from valuation and minority shareholder approval requirements [3]. Strategic Engagement - This financing round follows Predictmedix's active engagement with European capital markets, including participation in the 25th MK Investment Conference in Munich, aimed at expanding its shareholder base and building relationships with global investors [5]. - The company has also conducted a high-profile European road-show to engage influential family offices and institutional investors [5]. Company Overview - Predictmedix AI Inc. is an emerging provider of rapid health screening and remote patient care solutions, utilizing AI technology to analyze physiological data and predict various health issues [6]. - The company's Smarthealth AI stations can assess 19 physiological vital parameters and detect impairments due to drugs or alcohol, fatigue, or mental illnesses [6].

Core Viewpoint - Predictmedix AI Inc. is proposing a non-brokered private placement to raise up to C$900,000 by issuing up to 18,000,000 units at a price of C$0.05 per unit [1][2] Capital Raising and Use of Proceeds - The offering consists of units that include one common share and one half of a common share purchase warrant, with warrants allowing the purchase of additional shares at C$0.15 for 36 months [2] - The capital raised will enhance Predictmedix's core AI technology and support ongoing initiatives across its product ecosystem [3] Strategic Direction - The company is focused on advancing its Predictmedix Core AI Engine, which underpins multiple growth verticals, including AI-powered clinical trial applications, SmartHealth AI station certification initiatives, and B2C vital-scanning mobile platform development [3][8] Recent Corporate Activity - Following participation in the 25th MK Investment Conference in Munich, Predictmedix engaged with global investors and partners who showed strong interest in its AI-driven healthcare innovations [4][5] Company Overview - Predictmedix AI Inc. is a provider of rapid health screening and remote patient care solutions, utilizing AI technology to analyze physiological data and predict various health issues [6]

Core Insights - Predictmedix AI Inc. has launched a Clinical-Trial AI Platform aimed at enhancing efficiency in the $70 billion clinical trials market by helping pharmaceutical sponsors and contract research organizations (CROs) model, plan, and adapt clinical trials more effectively [1][4]. Company Overview - Predictmedix AI Inc. is an emerging leader in AI-powered health and safety technology, focusing on rapid health screening and remote patient care solutions globally [9]. - The company utilizes SmartHealth AI Stations, which employ multispectral cameras to analyze physiological data patterns and predict various health issues [9]. Product Features - The Clinical-Trial AI Platform is built on patented technology and high-fidelity datasets, designed to function as a real-time digital support system for trial planning [2]. - Key features include: - Adaptive Simulation Engine for running "what-if" scenarios and updating projections based on new data [6]. - Patient-Site Optimization to improve recruitment and reduce dropouts through AI recommendations [6]. - Cost & ROI Modeling to estimate budget impacts alongside predicted clinical outcomes [6]. - Interactive Dashboards for visualizing risk, cost, and patient flow [6]. - Compliance-Integrated AI to support audit and regulatory processes [6]. Market Context - The global clinical trials market is projected to exceed $70 billion by 2027, creating a demand for tools that can reduce trial failures, improve patient recruitment, and manage costs [4]. - The platform aims to address these industry needs with scalable, real-time analytics [4]. Distinctive Capabilities - The platform features continuous intelligence, end-to-end automation, multi-trial orchestration, and cost-outcome integration for unified decision support [7]. - It draws on over 500,000 SmartHealth scans, achieving approximately 95% accuracy for vital-sign detection [8].